1. Scrip
  2. >>Focus On Asia
  3. >>India

Semler Dirty Data: EMA Suspends Over 200 Products; Stings Indian CROs

 
• By Anju Ghangurde

Dirty data issues continue to plague Indian contract research organizations, denting the reputation of the beleaguered local industry and piling up challenges for marketing authorization holders. The European Medicines Agency (EMA) has now suspended close to 300 products that relied on flawed bioequivalence studies done by the Bengaluru-based Semler Research.

The EMA on July 22 recommended for suspension a long list medicines in various strengths based on a clutch of actives including erlotinib, saquinavir, celecoxib, eletriptan, duloxetine, amoxicillin and eprosartan for which bioequivalence studies were conducted at India's Semler Research Centre Private Ltd; marketing authorization holders for the suspended products include Sandoz NV, Teva Pharma Belgium NV, Mylan AB, Sanofi Aventis France, Zydus France, Ratiopharm GmbH and Glenmark.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

 
• By Dexter Jie Yan

While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By Lisa Takagi

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.